eCite Digital Repository

Prophylactic cefazolin dosing and surgical site infections: does the dose matter in obese patients?

Citation

Hussain, Z and Curtain, C and Mirkazemi, C and Gadd, K and Peterson, GM and Zaidi, STR, Prophylactic cefazolin dosing and surgical site infections: does the dose matter in obese patients?, Obesity Surgery, 29, (1) pp. 159-165. ISSN 0960-8923 (2019) [Refereed Article]


Preview
PDF
453Kb
  

Copyright Statement

Copyright 2018 The Authors. Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/

DOI: doi:10.1007/s11695-018-3497-0

Abstract

Background: Most surgical prophylaxis guidelines recommend a 3-g cefazolin intravenous dose in patients weighing ≥ 120 kg. However, this recommendation is primarily based on pharmacokinetic studies rather than robust clinical evidence. This study aimed to compare the prevalence of surgical site infections (SSIs) in obese and non-obese patients (body mass index ≥ 30 kg/m2 and < 30 kg/m2), and those weighing ≥ 120 kg and < 120 kg, who received 2- g cefazolin preoperatively.

Methods: A retrospective case-control study was conducted in adult elective surgical patients. Patients receiving 2- g cefazolin were grouped as obese and non-obese, and by weight (≥ 120 kg or < 120 kg). The 90-day prevalence of SSI and potential contributing factors were investigated.

Results: We identified 152 obese (median 134 kg) and 152 non-obese control (median 73 kg) patients. Baseline characteristics were similar between groups, except for an increased prevalence in the obese group of diabetes (35.5% vs 13.2%; p < 0.001) and an American Society of Anaesthesiologists Score of 3 (61.8% vs 17.1%; p < 0.001). While not statistically significant, the prevalence of SSI in the obese group was almost double that in the non-obese group (8.6% vs 4.6%; p = 0.25) and in patients weighing ≥ 120 kg (n = 102) compared to those weighing < 120 kg (n = 202) (9.8% vs 5.0%; p = 0.17).

Conclusion: The prevalence of SSI was not significantly increased in obese patients, or those weighing ≥ 120 kg, who received cefazolin 2- g prophylactically; however, trends toward an increase were evident. Large-scale randomised trials are needed to examine whether a 2-g or 3-g cefazolin is adequate to prevent SSI in obese (and ≥ 120 kg) individuals.

Item Details

Item Type:Refereed Article
Keywords:obese, elective surgery, cefazolin, drug dosing, surgical site infection, antibiotic prophylaxis
Research Division:Medical and Health Sciences
Research Group:Pharmacology and Pharmaceutical Sciences
Research Field:Clinical Pharmacology and Therapeutics
Objective Division:Health
Objective Group:Public Health (excl. Specific Population Health)
Objective Field:Nutrition
UTAS Author:Hussain, Z (Mr Zahid Hussain)
UTAS Author:Curtain, C (Mr Colin Curtain)
UTAS Author:Mirkazemi, C (Mrs Corinne Mirkazemi)
UTAS Author:Gadd, K (Dr Karl Gadd)
UTAS Author:Peterson, GM (Professor Gregory Peterson)
UTAS Author:Zaidi, STR (Dr Tabish Razi Zaidi)
ID Code:128616
Year Published:2019 (online first 2018)
Deposited By:Pharmacy
Deposited On:2018-10-03
Last Modified:2019-05-13
Downloads:28 View Download Statistics

Repository Staff Only: item control page